ArriVent BioPharma, Inc. (AVBP) vs Climb Bio, Inc. (CLYM)
A side-by-side comparison of ArriVent BioPharma, Inc. and Climb Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
CLYM
Climb Bio, Inc.
$10.68HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AVBP vs CLYM
growth of $100 · dividends reinvested · last 2yAVBP +2.6% (+1.3%/yr)CLYM +41.1% (+18.8%/yr)CLYM compounded faster over this window
AVBP CLYM
AVBP vs CLYM: by the numbers
- •AVBP is the larger company ($703M vs $612M market cap).
Metrics side by side
Valuation
| Metric | AVBP | CLYM |
|---|---|---|
| P/B ratio | 1.92 | 2.55 |
Profitability
| Metric | AVBP | CLYM |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.63% | -24.06% |
| ROIC | -47.96% | -26.94% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.